KT-621
KT621-AD-102
Phase 2 small_molecule active
Quick answer
KT-621 for Atopic Dermatitis is a Phase 2 program (small_molecule) at Kymera Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Kymera Therapeutics
- Indication
- Atopic Dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active